S-1/A: Silexion Therapeutics Files Amendment to S-1 Registration for Share Resale After Reverse Stock Split

Silexion Therapeutics is amending its S-1 registration statement to allow selling securityholders to resell up to 2,377,030 ordinary shares following a 1-for-9 reverse stock split.

Summary

• Silexion Therapeutics Corp has filed an amendment to its Form S-1 registration statement to register the resale of up to 2,377,030 ordinary shares by selling securityholders.
• The shares are issuable upon the exercise of warrants.
• The company will not receive any proceeds from the sale of these shares by the selling securityholders, except potentially from warrant exercises.
• Silexion effected a 1-for-9 reverse share split on November 27, 2024.
• The company is addressing Nasdaq compliance deficiencies related to minimum Market Value of Listed Securities and Market Value of Publicly Held Shares, with a deadline of May 19, 2025, to regain compliance.
• Silexion is an emerging growth company and a smaller reporting company, which allows for reduced disclosure obligations.
• The company's lead product candidate, SIL204, is in clinical development for KRAS-driven cancers, particularly locally advanced pancreatic cancer (LAPC).
• A Phase 2/3 trial for SIL204 in combination with chemotherapy is planned, with regulatory submission targeted for the first quarter of 2026 and trial initiation in the first half of 2026.
• The company's cash and cash equivalents were $1.2 million as of December 31, 2024, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as ongoing clinical development and efforts to address Nasdaq compliance, the financial situation and going concern doubts weigh heavily, resulting in a neutral to slightly negative outlook.

Positives

• SIL204 is in development for LAPC, with a Phase 2/3 trial planned.
• The company is working to regain compliance with Nasdaq listing requirements regarding minimum market value.
• The Phase 2 clinical trial with siG12DLoder showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting an overall survival advantage of 9.3 months.

Negatives

• The company had $1.2 million in cash and cash equivalents as of December 31, 2024, raising going concern doubts.
• The company is addressing Nasdaq compliance deficiencies related to minimum Market Value of Listed Securities and Market Value of Publicly Held Shares, with a deadline of May 19, 2025, to regain compliance.

Risks

• The company's independent auditor report contains an explanatory paragraph that expresses substantial doubt about the company's ability to continue as a going concern.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to shareholders.
• The company is heavily dependent on the success of its product candidates, which are in the early stages of preclinical or clinical development.
• The company faces intense competition and rapid technological change and the possibility that its competitors may develop therapies that are similar, more advanced, or more effective than theirs.
• Conditions in the Middle East and in Israel may harm the company's operations.
• If the company fails to maintain compliance with Nasdaq's continued listing requirements, its securities may be delisted from the Nasdaq Global Market.
• The price of the company's ordinary shares and its warrants may be volatile.

Future Outlook

The company plans to conduct a Phase 2/3 clinical trial for SIL204, with regulatory submission targeted for the first quarter of 2026 and trial initiation in the first half of 2026. The company expects to incur significant expenses and operating losses for the foreseeable future.

Industry Context

The document notes increasing competition in the biotechnology and pharmaceutical industries, particularly in the development of treatments targeting KRAS mutations. The company acknowledges the presence of major players and smaller companies in this space.

Comparison to Industry Standards

• The document mentions Bristol-Myers Squibb Company (through the recently acquired Mirati Therapeutics, Inc.), Revolution Medicines, Inc., AstraZeneca (in collaboration with Usynova), Boehringer and Gilead as competitors targeting KRAS mutations.
• The document notes that treatments for cancer currently include surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy.

Related Party Transactions

• The document details related party transactions including the A&R Sponsor Promissory Note, PIPE financing with Greenstar, LP, and transactions with GIBF.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• The company's financial condition raises concerns about its ability to continue operations, potentially impacting employees, suppliers, and other stakeholders.

Next Steps

• Initiate toxicology studies of SIL204 in 2025.
• Target regulatory submission in the first quarter of 2026 to initiate the Phase 2/3 trial.
• Target trial initiation in the first half of 2026.
• Apply for Orphan Drug Designation in both the U.S. and EU in 2026.

Key Dates

Keywords

Silexion Therapeutics, SIL204, KRAS, LAPC, Reverse Stock Split, S-1 Filing, Warrants, Nasdaq Compliance, Clinical Trial, RNAi, Oncology, Biotechnology